Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Diagnosis and Management of Multiple Sclerosis in Children



Najafi MR1, 3 ; Najafi MA2, 3 ; Nasr Z2
Authors

Source: Iranian Journal of Child Neurology Published:2016

Abstract

Growing evidence indicates the safety and well toleration of treatment by Disease-modifying in children suffering multiple sclerosis (MS). The treatment is not straight forward in a great number of patients, thus patients with pediatric MS must be managed by experienced specialized centers. Common treatments of multiple sclerosis for adults are first-line therapies. These therapies (firstline) are safe for children. Failure in treatment that leads to therapy alteration is almost prevalent in pediatric MS. Toleration against current second-line therapies has been shown in multiple sclerosis children. Oral agents have not been assessed in children MS patients. Although clinical trials in children are insufficient, immunomodulating managed children, experience a side effect similar to the adult MS patients. However, further prospective clinical studies, with large sample size and long follow-up are needed to distinguish the benefits and probable side effects of pediatric MS therapies. © 2016, Iranian Child Neurology Society. All rights reserved.
Related Docs
View other Related Docs
1. Confirmed Disability Progression As a Marker of Permanent Disability in Multiple Sclerosis, European Journal of Neurology (2022)
2. Comparing the Efficacy of Monthly Cyclophosphamide As Monotherapy Versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis, Journal of Isfahan Medical School (2017)
3. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (10)
Masoud Etemadifar (8)
Other Related Docs
4. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study, Neurology (2024)
5. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
6. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
7. Prognostic Indicators in Pediatric Clinically Isolated Syndrome, Annals of Neurology (2017)
8. Early-Onset Multiple Sclerosis in Isfahan, Iran: Report of the Demographic and Clinical Features of 221 Patients, Journal of Child Neurology (2016)
9. Safety and Efficacy of Mitoxantrone in Pediatric Patients With Aggressive Multiple Sclerosis, European Journal of Paediatric Neurology (2014)
10. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)
11. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
12. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
13. Pediatric Multiple Sclerosis With Primary Progressive Course-Report of a Retrospective Cohort Study in Iran, Neuropediatrics (2013)
14. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
15. Incidence and Prevalence of Multiple Sclerosis in Persian Gulf Area: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2020)
16. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
17. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
18. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018, CNS Drugs (2021)
19. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
20. Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis, BMC Medical Research Methodology (2022)